H.R. 1193 · 117th Congress · House

Cardiovascular Advances in Research and Opportunities Legacy Act

Enacted· Became Public Law No: 117-244.
Introduced
Feb 22, 21
Passed House
Dec 8, 21
Passed Senate
Dec 1, 22
Sent to President
Dec 16, 22
Signed into Law
Dec 20, 22

Executive Summary

Cardiovascular Advances in Research and Opportunities Legacy Act

This act addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

Previous Versions

59Dec 5, 2022

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

55Dec 1, 2022

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

25Jul 12, 2022

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

53Dec 8, 2021

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.

The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.

00Feb 22, 2021

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.

The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.

Action Timeline

40
  1. DEC 20, 2022BecameLaw

    Signed by President.

  2. DEC 20, 2022President

    Signed by President.

  3. DEC 20, 2022BecameLaw

    Became Public Law No: 117-244.

    117Yea
    244Nay
    0NV
  4. DEC 20, 2022President

    Became Public Law No: 117-244.

    117Yea
    244Nay
    0NV
  5. DEC 16, 2022President

    Presented to President.

  6. DEC 16, 2022Floor

    Presented to President.

  7. DEC 05, 2022Floor

    Message on Senate action sent to the House.

  8. DEC 05, 2022ResolvingDifferences

    Mr

    Pallone moved that the House suspend the rules and agree to the Senate amendment. (consideration: CR H8755-8756)

    8755Yea
    8756Nay
    0NV
  9. DEC 05, 2022Floor

    DEBATE - The House proceeded with forty minutes of debate on the Senate amendment to H.R. 1193.

  10. DEC 05, 2022NotUsed

    Resolving differences -- House actions

    On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote.

  11. DEC 05, 2022ResolvingDifferences

    On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H8755)

  12. DEC 05, 2022ResolvingDifferences

    Motion to reconsider laid on the table Agreed to without objection.

  13. DEC 01, 2022Floor

    Measure laid before Senate by unanimous consent

    (consideration: CR S6946-6947)

    6946Yea
    6947Nay
    0NV
  14. DEC 01, 2022Floor

    The committee substitute withdrawn by Unanimous Consent.

  15. DEC 01, 2022Floor

    Passed/agreed to in Senate

    Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S6947)

  16. DEC 01, 2022Floor

    Passed Senate with an amendment by Unanimous Consent

    (text of amendment in the nature of a substitute: CR S6947)

  17. JUL 12, 2022Committee

    Committee on Health, Education, Labor, and Pensions

    Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.

  18. JUL 12, 2022Committee

    Committee on Health, Education, Labor, and Pensions

    Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.

  19. JUL 12, 2022Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.

  20. JUN 14, 2022Committee

    Committee on Health, Education, Labor, and Pensions

    Ordered to be reported without amendment favorably.

  21. MAY 25, 2022IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  22. DEC 09, 2021IntroReferral

    Received in the Senate.

  23. DEC 08, 2021Committee

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-212.

    117Yea
    212Nay
    0NV
  24. DEC 08, 2021Committee

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-212.

    117Yea
    212Nay
    0NV
  25. DEC 08, 2021Calendars

    Placed on the Union Calendar, Calendar No. 153.

  26. DEC 08, 2021Floor

    Mr

    Pallone moved to suspend the rules and pass the bill, as amended.

  27. DEC 08, 2021Floor

    Considered under suspension of the rules

    (consideration: CR H7518-7522)

    7518Yea
    7522Nay
    0NV
  28. DEC 08, 2021Floor

    DEBATE - The House proceeded with forty minutes of debate on H.R. 1193.

  29. DEC 08, 2021Floor

    Passed/agreed to in House

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H7518)

  30. DEC 08, 2021Floor

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7518)

  31. DEC 08, 2021Floor

    Motion to reconsider laid on the table Agreed to without objection.

  32. DEC 08, 2021Floor

    The title of the measure was amended

    Agreed to without objection.

  33. NOV 17, 2021Committee

    Committee Consideration and Mark-up Session Held.

  34. NOV 17, 2021Committee

    Ordered to be Reported (Amended) by Voice Vote.

  35. NOV 04, 2021Committee

    Subcommittee Consideration and Mark-up Session Held.

  36. NOV 04, 2021Committee

    Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

  37. FEB 23, 2021Committee

    Referred to the Subcommittee on Health.

  38. FEB 22, 2021IntroReferral

    Introduced in House

  39. FEB 22, 2021IntroReferral

    Introduced in House

  40. FEB 22, 2021IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

9

Health, Education, Labor, and Pensions Committee

sshr00

Referred: Jul 12, 2022

Active

Health, Education, Labor, and Pensions Committee

sshr00

Referred: Jun 14, 2022

Active

Health, Education, Labor, and Pensions Committee

sshr00

Referred: May 25, 2022

Active

Energy and Commerce Committee

hsif00

Referred: Dec 8, 2021

Active

Energy and Commerce Committee

hsif00

Referred: Nov 17, 2021

Active

Health Subcommittee

hsif14

Referred: Nov 4, 2021

Active

Health Subcommittee

hsif14

Referred: Nov 4, 2021

Active

Health Subcommittee

hsif14

Referred: Feb 23, 2021

Active

Energy and Commerce Committee

hsif00

Referred: Feb 22, 2021

Active